Trials / Terminated
TerminatedNCT01774253
Erivedge (Vismodegib) in the Treatment of Pediatric Patients With Refractory Pontine Glioma
A Phase II, Open-label, Multi-center Study of Erivedge (Vismodegib) in the Treatment of Pediatric Patients With Refractory Pontine Glioma.
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 9 (actual)
- Sponsor
- Giselle Sholler · Academic / Other
- Sex
- All
- Age
- 3 Years – 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this research study is to evaluate an investigational drug (Vismodegib) for Pontine Glioma that is growing or has come back (reoccurred). This study will look at the tumors response to the study drug, Vismodegib, and will also look at the safety and tolerability of Vismodegib. Vismodegib has been tested in multiple adult clinical trials and one pediatric trial. Laboratory testing in pontine gliomas suggests that this drug may be effective in treating this disease.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Vismodegib |
Timeline
- Start date
- 2013-05-01
- Primary completion
- 2015-10-01
- Completion
- 2015-10-01
- First posted
- 2013-01-23
- Last updated
- 2024-08-06
- Results posted
- 2016-10-28
Locations
2 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT01774253. Inclusion in this directory is not an endorsement.